<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01529528</url>
  </required_header>
  <id_info>
    <org_study_id>CWP-DIANA-301</org_study_id>
    <nct_id>NCT01529528</nct_id>
  </id_info>
  <brief_title>A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients</brief_title>
  <acronym>CWP-DIANA-301</acronym>
  <official_title>A Multicenter, Randomized, Double Blind, Placebo Controlled, Therapeutic Confirmatory Trial(Phase 3) to Evaluate Efficacy and Safety of CWP-0403 in Type 2 DM Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is to evaluate the efficacy and safety of CWP-0403 at 100 mg or 200 mg twice daily
      compared with placebo in type 2 diabetic patients with inadequate glycemic control by diet
      therapy or combination of diet and exercise therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change in HbA1c from baseline to week24</measure>
    <time_frame>0wk, 8wk, 16wk, 24wk</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving HbA1c&lt;6.5% at week24</measure>
    <time_frame>0wk, 8wk, 16wk, 24wk</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving HbA1c&lt;7% at week24</measure>
    <time_frame>0wk, 8wk, 16wk, 24wk</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline to week 24: Fasting plasma glucose</measure>
    <time_frame>0wk, 24wk</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline to week 24 in Fasting serum insulin</measure>
    <time_frame>0 wk, 24 wk</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline to week 24 in Fasting serum pro-insulin</measure>
    <time_frame>0 wk, 24wk</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in from baseline to week 24 fasting serum c-peptide</measure>
    <time_frame>0wk, 24wk</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline to week 24 in HOMA-β</measure>
    <time_frame>owjm 24wk</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline to week 24 in HOMA-IR</measure>
    <time_frame>0wk, 24 wk</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo of CWP-0403 100mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of CWP-0403 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CWP-0403 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CWP-0403 200mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CWP-0403 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CWP-0403 100mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anagliptin</intervention_name>
    <description>Anagliptin 100mg, tablet, BID</description>
    <arm_group_label>CWP-0403 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anagliptin</intervention_name>
    <description>Anagliptin 100mg, tablet, BID</description>
    <arm_group_label>CWP-0403 200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Anagliptin</intervention_name>
    <description>Placebo of Anagliptin 100mg, tablet, BID</description>
    <arm_group_label>Placebo of CWP-0403 100mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 DM patients

          -  Subjects who couldn't control the blood glucose despite of a dietary and exercise
             therapy more than 6 weeks at screening visit

          -  FPG ≤ 270mg/dL at screening visit

          -  Patients who consent to participate in this trial by written Informed Consent Form

        Exclusion Criteria:

          -  Type 1 DM or secondary diabetes

          -  Subjects who are administrating insulin or need to insulin therapy

          -  History of oral anti-hyperglycemic drugs within 6 weeks before screening visit

          -  Body mass index &lt; 20 kg/m2 or &gt; 40.0kg/m2

          -  Subjects who are assessed to be inappropriate for this trial by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung Woo Park, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kangbuk Samsung Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2012</study_first_submitted>
  <study_first_submitted_qc>February 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2012</study_first_posted>
  <last_update_submitted>January 2, 2013</last_update_submitted>
  <last_update_submitted_qc>January 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CWP-0403</keyword>
  <keyword>type 2 DM</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Phase 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

